• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

[The guideline of prevention and treatment for hepatitis C: a 2015 update].

作者信息

Wei Lai, Hou Jin-Lin

机构信息

Peking University People's Hospital, Peking University Hepatology Institute, Beijing 100044, China.

Nanfang Hospital, Southern Medical University, Guangzhou, 510515, China.

出版信息

Zhonghua Gan Zang Bing Za Zhi. 2015 Dec;23(12):906-23. doi: 10.3760/cma.j.issn.1007-3418.2015.12.003.

DOI:10.3760/cma.j.issn.1007-3418.2015.12.003
PMID:26739465
Abstract
摘要

相似文献

1
[The guideline of prevention and treatment for hepatitis C: a 2015 update].《丙型肝炎防治指南：2015年更新版》
Zhonghua Gan Zang Bing Za Zhi. 2015 Dec;23(12):906-23. doi: 10.3760/cma.j.issn.1007-3418.2015.12.003.
2
[Guidelines for the prevention and treatment of hepatitis C (2019 version)].丙型肝炎防治指南（2019年版）
Zhonghua Gan Zang Bing Za Zhi. 2019 Dec 20;27(12):962-979. doi: 10.3760/cma.j.issn.1007-3418.2019.12.008.
3
HEP DART 2005 -- HCV therapeutics.2005年丙型肝炎直接抗病毒治疗——丙型肝炎病毒疗法
IDrugs. 2006 Mar;9(3):168-70.
4
Toward evidence based control of hepatitis C virus infection.迈向基于证据的丙型肝炎病毒感染控制
Adv Drug Deliv Rev. 2007 Oct 10;59(12):1195. doi: 10.1016/j.addr.2007.08.002. Epub 2007 Aug 11.
5
[Interpretation of the important update of the Guideline for the prevention and treatment of hepatitis C (2022 edition)].[《丙型肝炎防治指南（2022年版）》重要更新解读]
Zhonghua Gan Zang Bing Za Zhi. 2023 Jul 20;31(7):688-691. doi: 10.3760/cma.j.cn501113-20230529-00233.
6
[Guideline of prevention and treatment of hepatitis C].[丙型肝炎防治指南]
Zhonghua Yu Fang Yi Xue Za Zhi. 2004 May;38(3):210-5.
7
[Guideline for the prevention and treatment of hepatitis C (2022 version)].《丙型肝炎防治指南（2022年版）》
Zhonghua Gan Zang Bing Za Zhi. 2022 Dec 20;30(12):1332-1348. doi: 10.3760/cma.j.cn501113-20221220-00605.
8
Japanese Society for Dialysis Therapy: clinical practice guidelines for the prevention, diagnosis, evaluation, and treatment of hepatitis C.日本透析治疗学会：丙型肝炎预防、诊断、评估及治疗的临床实践指南
Ther Apher Dial. 2012 Aug;16(4):287-8. doi: 10.1111/j.1744-9987.2012.01095.x.
9
Will there be an HCV meeting in 2020? Summary of the 17th international meeting on hepatitis C virus and related viruses.2020年是否会有丙型肝炎病毒会议？第17届丙型肝炎病毒及相关病毒国际会议总结
Gastroenterology. 2011 Jul;141(1):e1-5. doi: 10.1053/j.gastro.2011.05.027. Epub 2011 May 24.
10
New guidelines on hepatitis C.丙型肝炎新指南。
BMJ. 1997 Apr 12;314(7087):1070. doi: 10.1136/bmj.314.7087.1065i.

引用本文的文献

1
Regression in hepatic fibrosis in elderly Chinese patients with hepatitis C receiving direct-acting antiviral treatment.老年丙型肝炎患者接受直接作用抗病毒治疗后肝纤维化消退。
BMC Gastroenterol. 2023 Apr 3;23(1):102. doi: 10.1186/s12876-023-02732-4.
2
HCV inhibits M2a, M2b and M2c macrophage polarization via HCV core protein engagement with Toll-like receptor 2.丙型肝炎病毒通过丙型肝炎病毒核心蛋白与Toll样受体2结合来抑制M2a、M2b和M2c巨噬细胞极化。
Exp Ther Med. 2022 Jun 16;24(2):522. doi: 10.3892/etm.2022.11448. eCollection 2022 Aug.
3
Shifting Epidemiology of Hepatocellular Carcinoma in Far Eastern and Southeast Asian Patients: Explanations and Implications.
远东和东南亚患者肝细胞癌流行病学的变化：解释与影响
Curr Oncol Rep. 2022 Feb;24(2):187-193. doi: 10.1007/s11912-021-01160-5. Epub 2022 Jan 21.
4
Prevalence, diagnosis, and treatment of hepatitis C in Mainland China.中国大陆丙型肝炎的患病率、诊断与治疗
Glob Health Med. 2021 Oct 31;3(5):270-275. doi: 10.35772/ghm.2021.01080.
5
Supervised Analysis of Hepatitis C Virus RNA-Positive Case Reporting in County-Level Hospitals - China, 2013-2018.2013 - 2018年中国县级医院丙型肝炎病毒RNA阳性病例报告的监督分析
China CDC Wkly. 2020 Jul 31;2(31):587-590. doi: 10.46234/ccdcw2020.157.
6
Sofosbuvir-based therapies in genotype 2 hepatitis C virus cirrhosis: A real-life experience with focus on ribavirin dose.基于索非布韦的治疗方案在基因型 2 丙型肝炎病毒肝硬化中的应用：一项真实世界经验，重点关注利巴韦林剂量。
Pharmacol Res Perspect. 2021 Aug;9(4):e00811. doi: 10.1002/prp2.811.
7
Association of macrophage inhibitory factor -1 polymorphisms with antiviral efficacy of type 1b chronic hepatitis C.巨噬细胞抑制因子-1基因多态性与1b型慢性丙型肝炎抗病毒疗效的关联
Mol Cell Biochem. 2021 Jun;476(6):2439-2447. doi: 10.1007/s11010-021-04097-2. Epub 2021 Feb 18.
8
Population Pharmacokinetic Analysis of Yimitasvir in Chinese Healthy Volunteers and Patients With Chronic Hepatitis C Virus Infection.依米他韦在中国健康志愿者和慢性丙型肝炎病毒感染患者中的群体药代动力学分析。
Front Pharmacol. 2021 Jan 28;11:617122. doi: 10.3389/fphar.2020.617122. eCollection 2020.
9
Changes of Gut-Microbiota-Liver Axis in Hepatitis C Virus Infection.丙型肝炎病毒感染中肠道微生物群-肝脏轴的变化
Biology (Basel). 2021 Jan 13;10(1):55. doi: 10.3390/biology10010055.
10
Levels of serum IgG subclasses in patients with liver disease: A retrospective study.肝病患者血清IgG亚类水平：一项回顾性研究。
Exp Ther Med. 2021 Jan;21(1):45. doi: 10.3892/etm.2020.9476. Epub 2020 Nov 17.